• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Tressler Nick B. was granted 11,712 shares (SEC Form 4)

    7/2/26 4:17:25 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTGN alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Tressler Nick B.

    (Last)(First)(Middle)
    C/O VISTAGEN THERAPEUTICS, INC.
    343 ALLERTON AVENUE

    (Street)
    SOUTH SAN FRANCISCO CALIFORNIA 94080

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Vistagen Therapeutics, Inc. [ VTGN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Financial Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    06/30/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock06/30/2026A(1)V11,712A$0.192111,712D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).
    /s/ Nick B. Tressler07/02/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $VTGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTGN

    DatePrice TargetRatingAnalyst
    12/17/2025$0.90Buy → Hold
    Jefferies
    12/17/2025Buy → Hold
    Maxim Group
    12/17/2025Outperform → Mkt Perform
    William Blair
    12/17/2025$1.00Buy → Hold
    Stifel
    12/7/2023$15.00Hold → Buy
    Jefferies
    8/7/2023$30.00Hold → Buy
    Maxim Group
    7/22/2022Outperform → Neutral
    Robert W. Baird
    7/22/2022Buy → Hold
    Jefferies
    More analyst ratings

    $VTGN
    SEC Filings

    View All

    Vistagen Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    6/30/26 8:28:42 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    6/17/26 5:13:49 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Vistagen Therapeutics Inc.

    10-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    6/15/26 4:50:15 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

    Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder Favorable safety and tolerability data were consistent with previous clinical trials Company plans to meet with FDA to discuss a potential registrational pathway for fasedienol involving a single future Phase 3 trial with the Liebowitz Social Anxiety Scale as the primary endpoint and confirmatory evidence from the PALISADE Program Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscien

    6/30/26 8:00:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

    Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026 Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial Received FDA "Study May Proceed" letter under refisolone Investigational New Drug (IND) application to support further clinical development in the U.S. for treatment of moderate to severe vasomotor symptoms (hot flashes) due to

    6/15/26 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company's clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures as recommended under ICH E1, the international regulatory standard governing safety database exposure recommendations for drugs intended for long-term treatment (chronic or repeated intermittent use for longer than 6 months) of non-life-threatening conditions1. As of May 31, 2026, the Company estimates

    6/9/26 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Adler Reid G. was granted 36,818 shares, increasing direct ownership by 153% to 60,868 units (SEC Form 4)

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    7/2/26 4:34:09 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Tressler Nick B. was granted 11,712 shares (SEC Form 4)

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    7/2/26 4:17:25 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Singh Shawn was granted 36,818 shares, increasing direct ownership by 204% to 54,846 units (SEC Form 4)

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    7/2/26 4:16:44 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    VistaGen downgraded by Jefferies with a new price target

    Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90

    12/17/25 2:23:33 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by Maxim Group

    Maxim Group downgraded VistaGen from Buy to Hold

    12/17/25 12:23:57 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by William Blair

    William Blair downgraded VistaGen from Outperform to Mkt Perform

    12/17/25 11:34:15 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

    Dr. Angelov brings extensive industry experience across multiple therapeutic areas Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. "We are pleased to welcome Dr. Angelov to the Vistagen team," said President and Chief Executive Officer of Vistagen, Shawn Singh. "His two decades of leadership across clinical development and medical affairs, including roles at Karuna, Neurocrine, Novartis, and Teva, wil

    5/19/26 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Vistagen Appoints Paul Edick to its Board of Directors

    Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors ("Board"). Following the appointment of Mr. Edick, Vistagen's Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. "We are pleased to welcome Mr. Edick to our Board of Directors," said Maggie FitzPatrick,

    10/29/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Financials

    Live finance-specific insights

    View All

    Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

    Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder Favorable safety and tolerability data were consistent with previous clinical trials Company plans to meet with FDA to discuss a potential registrational pathway for fasedienol involving a single future Phase 3 trial with the Liebowitz Social Anxiety Scale as the primary endpoint and confirmatory evidence from the PALISADE Program Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscien

    6/30/26 8:00:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

    PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

    2/12/26 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 12, 2026, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 third quarter ended December 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at

    2/4/26 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    11/14/24 5:05:41 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    11/14/24 4:19:46 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by VistaGen Therapeutics Inc. (Amendment)

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    2/14/24 6:18:34 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care